Also found in: Dictionary.


Fenofibrate, see there.
Mentioned in ?
References in periodicals archive ?
LCP-Feno (containing 145 mg / 48 mg active substance) is being developed as a potential AB-rated, substitutable version of Tricor 145 mg and 48 mg, which is currently marketed in the US by Abbott and in Europe by Solvay under the name Lipanthyl.
Following the acquisition of Fournier Pharma, Solvay Pharmaceuticals flagship product and principal growth driver is now fenofibrate, a treatment for lipidic disorders which is sold as Tricor in the US and Lipanthyl elsewhere.